Shots:
Brii Bio launched amubarvimab + romlusevimab in China as a long-acting COVID-19 neutralizing Ab therapy based on the approval granted by NMPA in Dec’21 for the treatment of adults/pediatric patients (aged 12-17yrs, 40kg) with mild/normal COVID-19
The approval was based on the P-III (ACTIV-2) trial evaluating amubarvimab + romlusevimab vs PBO in 837 patients with results demonstrating an 80% reduction in hospitalization/death @28days & improved safety
Amubarvimab and romlusevimab are non-competing SARS-CoV-2 neutralizing mAb extracted from the recovered COVID-19 patients. This combination therapy was jointly developed by Brii Bio, the 3rd People’s Hospital of Shenzhen & Tsinghua University
Ref: PRNewswire | Image: Brii Biosciences
